Top Page | English | 简体中文 | 繁體中文 | 한국어 | 日本語
Thursday, 5 August 2021, 10:45 HKT/SGT

Source: Eisai
Eisai Receives Award for Excellence in Corporate Communications at the 37th Corporate Communications Awards

TOKYO, Aug 5, 2021 - (JCN Newswire) - Eisai Co., Ltd. announced today that it has received the Award for Excellence in Corporate Communications at the 37th annual Corporate Communications Awards, hosted by the Japan Institute for Social and Economic Affairs, an affiliate of the Japanese Business Federation (Tokyo).

The Corporate Communications Awards were established in 1984 with the aim of advancing the field by recognizing companies and individuals that practice excellent corporate communications. There are three awards: the Award for Excellence in Corporate Communications, Outstanding Leadership Awards in Corporate Communications, and the Outstanding Merit Awards.

The Award for Excellence in Corporate Communications received by Eisai is given to the company that contribute to society by identifying what is expected and required of them by society, reflecting this in their management, and disseminating and communicating accurate information about their corporate activities to their stakeholders through public relations initiatives.

The award was presented to Eisai in recognition of its efforts to promote understanding of dementia, which has become a social issue, by providing not only information on the status of new drug development, but also on the latest findings on the pathological condition of the disease and the social burden of nursing care, as well as efforts to promote understanding among stakeholders through study sessions for scientific and medical journalists and providing easy-to-understand explanations of difficult science, thereby making a significant contribution to increase the benefits of patients and their families in line with its corporate philosophy of human health care (hhc).

Eisai's corporate philosophy is to give first thought to patients and their families, and increase the benefits that health care provides, and Eisai calls this philosophy the "human health care (hhc)" philosophy, in one word. In the new medium-term business plan "EWAY Future & Beyond" started in FY2021, based on the hhc philosophy, Eisai aims to remove the anxiety of "The People", including not only patients but also society at large, by delivering not only pharmaceutical products but also solutions to The People. In order to realize the hhc philosophy, we will make further contributions to increase the benefits to "The People" by enhancing corporate value through public relations activities.

Media Inquiries:
Public Relations Department,
Eisai Co., Ltd.

Topic: Press release summary
Source: Eisai

Sectors: BioTech
From the Asia Corporate News Network

Copyright © 2021 ACN Newswire. All rights reserved. A division of Asia Corporate News Network.

Dec 6, 2021 11:30 HKT/SGT
Eisai to Present Abstracts on Oncology Products And Pipeline at 44th Annual San Antonio Breast Cancer Symposium
Nov 30, 2021 09:13 HKT/SGT
Eisai and FCNT Enter Into Business Alliance Aiming to Support People Living with Dementia and to Prevent Dementia
Nov 30, 2021 08:56 HKT/SGT
Eisai to Present Latest Data on Perampanel and E2730 at the 75th American Epilepsy Society Annual Meeting
Nov 29, 2021 11:44 HKT/SGT
European Commission Approves LENVIMA (lenvatinib) Plus KEYTRUDA (pembrolizumab) for Patients With Certain Types of Endometrial Carcinoma
Nov 29, 2021 09:15 HKT/SGT
European Commission Approves LENVIMA (lenvatinib) Plus KEYTRUDA (pembrolizumab) as First-Line Treatment for Adult Patients With Advanced Renal Cell Carcinoma
Nov 18, 2021 14:28 HKT/SGT
Eisai Receives the 'Most Liked!' IR Award at The 2021 IR Award
Nov 12, 2021 15:10 HKT/SGT
Eisai: New Phase 3 Data Show Positive Correlation Between ADUHELM Treatment Effect on Biomarkers and Reduction in Clinical Decline in Alzheimer's Disease
Nov 12, 2021 14:31 HKT/SGT
Eisai Presents New Analysis of Lecanemab Clinical Efficacy Results from Phase 2b Study at Clinical Trials On Alzheimer's Disease (CTAD) Conference
Nov 12, 2021 14:03 HKT/SGT
Eisai: Introduction of Plasma-based Biomarker Screening to Facilitate Identification of Subjects for Phase 3 Ahead 3-45 Trial Presented at Clinical Trials on Alzheimer's Disease (CTAD) Conference
Nov 11, 2021 11:05 HKT/SGT
Eisai Presents Late-Breaker Updates on Lecanemab Clinical, Biomarker and Safety Data from Phase 2b Study Core and Open-Label Extension
More news >>
 News Alerts
Copyright © 2021 ACN Newswire - Asia Corporate News Network
Home | About us | Services | Partners | Events | Login | Contact us | Privacy Policy | Terms of Use | RSS
US: +1 214 890 4418 | Beijing: +86 400 879 3881 | Hong Kong: +852 8192 4922 | Singapore: +65 6549 7068 | Tokyo: +81 3 6859 8575

Connect With us: